Special volume negotiation is the first in China, video exposure! There are pharmaceutical companies on behalf of the scene tears!

Author: on the morning of January 9, situ Yangming was the negotiation date for the purchase of insulin belt in Wuhan Soon, Wuhan Evening News, Changjiang Daily and other media released live negotiation videos Just 1 minute and 28 seconds of video, revealing a huge amount of information In the video, negotiation experts repeatedly emphasized that Wuhan negotiation is a pilot project of the National Health Insurance Bureau, a negotiation on behalf of the National Bureau, and a pilot project of the National Health Insurance Bureau After the negotiation, the results will be reported to the National Health Insurance Bureau immediately In the video, enterprises are only willing to reduce the price by a few percentage points, which is obviously not satisfactory For example, negotiation experts said Lilly was very cooperative and the decline was more than they expected "And you? Remind you to think again " The video ended with tough negotiation experts (the above content was sorted out according to the video uploaded by Wuhan Evening News, but the video has been deleted at present) Some content can also be seen in the video of Changjiang Daily, just like the national volume procurement negotiation, but also the tears of enterprise representatives at the negotiation site Photo source: Changjiang Daily Wuhan is the main drug for diabetes - insulin is included in the volume purchase for the first time Media analysis said that there had been a voice that although the amount of insulin used was large, due to the complex production process, the possibility of insulin entering the belt volume purchase was not great If, as the experts emphasized, the negotiation is a pilot project of the National Health Insurance Bureau, it may mean that the current volume purchase in Wuhan is to pave the way for a larger scale of insulin volume purchase Wuhan Evening News also partially implied this logic in its report "The first talk in China on insulin specific bargaining", in the video, the subtitle map of Wuhan Evening News and the statement of National Health Insurance Bureau pilot, a negotiation expert, are corroborating each other After the high blood pressure and diabetes drugs are included in the outpatient reimbursement scope, the author speculates that this negotiation in Wuhan may become the "Sanming mode" for the volume purchase of non evaluated products It will be a model for the volume purchase of all products with high blood pressure and diabetes, and its negotiation and price reduction rules will be used for reference by all regions Shake 7 billion market: the decline is linked to the market capacity On November 29, 2019, Wuhan established a volume Procurement Alliance, and then (December 1) released the draft for comments on the implementation rules of volume procurement On December 9, the implementation rules of volume procurement in Wuhan were officially released, and a total of 45 products were purchased with volume, of which insulin was negotiated separately According to media reports, on January 8, 2020, the head of Wuhan Medical Insurance Bureau introduced that the results of bid opening for the first batch of drugs in Wuhan were released, 39 of the 44 generic names (excluding insulin) were successfully purchased; compared with the lowest price in China, the average decrease was 31%, and the maximum single product decrease was 93% There are 18 original imported varieties selected Compared with the lowest price in China, the average decline is 20.15%, and the maximum decline of original drugs is 43.45% On January 9 today, we are going to purchase insulin According to documents previously released by Wuhan City, the negotiation involved more than 1.7 million insulin, involving nine enterprises, including pharmaceutical enterprises Novo Nordisk, Lilly Suzhou pharmaceutical, Tonghua Dongbao pharmaceutical, UL, Yuheng pharmaceutical, Sanofi (Beijing) pharmaceutical, and Ganli pharmaceutical At present, the negotiation results have not been published, but from the video information, Lilly's decline is more than expected, and the specific price reduction is expected to further disclose the information According to the data quoted by Wuhan Evening News, insulin is the most widely used drug for diabetes In 2018, in China's 6.77 billion yuan diabetes drug market, insulin and its similar drugs accounted for more than 37%, more than 2.5 billion yuan According to the estimation of Zhongtai securities, according to the current median price of each group of products, the total amount of insulin belt purchase in Wuhan is about 130 million yuan Due to the limited market scale, there is no requirement for the price reduction Even if the price is not reduced, the market can continue to be supplied, but some markets need to be allocated to other enterprises: 1) if the reduction is less than 5%, more than 50% of the corresponding products will be allocated to enterprises in the same group in 2018; 2) if the reduction is between 5-10%, 70% of the original market share can be directly obtained; 3) If the decrease is more than 10%, 90% of the original market share can be obtained directly; 4) the remaining part of each product in the same group will enter the total substitution amount, which will be distributed by 50%, 30% and 20% of the total substitution amount, and the top three (absolute amount) with the highest decrease can be obtained Compared with other 44 varieties purchased in Wuhan, the price reduction requirement is very moderate, with a decrease of less than 5% In principle, even if the decrease of 0% means no price reduction, 50% of the market can be kept In the video, the relevant enterprises only cut the price by a few percentage points Obviously, they want to keep half of the market at the lowest price It is reasonable that the negotiation experts are not satisfied Wuhan, the "Sanming model" in the field of volume purchasing? "The first talk on special insulin belt price negotiation in China", the background of Wuhan insulin belt purchase is that the national level is concerned about "two diseases" (diabetes, hypertension) drug use In October 2019, the state health insurance bureau, the Ministry of finance, the health and Health Commission and the Drug Administration jointly issued the guidance on improving the drug use guarantee mechanism of urban and rural residents' outpatient service for hypertension and diabetes, which made it clear that the cost of blood pressure and hypoglycemic drugs in outpatient service of medical institutions for hypertension and diabetes insured patients should be paid by the overall fund, and the proportion of payment within the overall fund policy reached To more than 50% At a press conference held by the State Council's new office, the country's relevant leaders said that a series of reforms should be carried out to improve drug prices, such as the implementation of national bidding procurement for drugs through consistency evaluation However, not all drugs have passed the consistency evaluation and have the qualification of purchasing with quantity organized by the state As a national pilot, one of the most important characteristics of Wuhan city's volume procurement is to implement the centralized volume procurement for the drugs that have not been evaluated The drugs under the same general name are divided into the original research and imitation two types for the centralized volume procurement, which is the first in China Insulin products obviously have this characteristic The author speculates that in the future, the special negotiation represented by insulin will continue to be promoted on the basis of the "national first talk" pilot, like the "Sanming model", and become a sample of recruitment and acquisition in various regions In the future, the procurement of varieties may not be limited to insulin alone, but will be extended to all diabetes and hypertension drugs The procurement of over assessed band is organized by the state, and the procurement of non assessed band is organized by the local government with reference to Wuhan pilot Under the condition that the national rules for belt quantity procurement have been made clear, Wuhan rules will become a model for the local belt quantity procurement of non evaluated varieties According to the summary of the relevant person in charge of Wuhan Medical Insurance Bureau, in addition to the quantity purchase aimed at non over evaluated varieties, the other two characteristics are: the combination of dosage forms to maximize the degree of competition of drugs; according to the gradient of the price reduction range, different purchase quantities are given according to the different price reduction range, fully reflecting the relationship between quantity and price, reflecting the linkage between quantity and price, which is the first in China Attached: Wuhan insulin group, purchasing volume and corresponding pharmaceutical enterprise group 37